GlassScriptPhysician profile
Anny Xiao
NPI 1396278156
$7,029.44
in general payments reported to CMS, 2019-2025
31 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $270 · 2021: $838 · 2022: $1,384 · 2023: $1,226 · 2024: $848 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Travel and Lodging: $2.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.67 |
| Travel and Lodging | $2.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $774.57 | 2021-2025 | Opzelura |
| Abbvie INC. | $707.15 | 2019-2025 | |
| Genzyme Corporation | $628.41 | 2022-2025 | |
| Pfizer INC. | $577.59 | 2019-2024 | |
| Lilly USA, LLC | $434.83 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Galderma Laboratories, L.P. | $348.55 | 2019-2025 | Aklief |
| Amgen INC. | $345.03 | 2021-2024 | Otezla |
| Celgene Corporation | $326.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $300.13 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $274.61 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $240.41 | 2020 | |
| Journey Medical Corporation | $212.32 | 2025 | Emrosi |
| Sun Pharmaceutical Industries INC. | $178.43 | 2022-2025 | Blu-U, Odomzo, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.73 | 2019 | |
| Dermavant Sciences, INC. | $176.36 | 2023 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $170.03 | 2023-2025 | |
| Janssen Biotech, INC. | $167.80 | 2022-2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $160.05 | 2025 | Zoryve |
| Dermira, INC. | $123.55 | 2019 | |
| Ucb, INC. | $114.79 | 2024 | Bimzelx |
| Allergan, INC. | $97.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.60 | 2022 | |
| Biofrontera INC. | $89.79 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $79.52 | 2021-2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $63.93 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $41.38 | 2024 | Ycanth |
| Organon LLC | $31.07 | 2025 | |
| Revance Therapeutics, INC. | $28.39 | 2024 | Daxxify |
| Almirall LLC | $27.37 | 2025 | Klisyri |
| Sanofi-Aventis U.S. LLC | $21.56 | 2021 | |
| Botanix Sb INC | $19.15 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anny Xiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.